| KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 192 | 2020 |
| Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives G Barchiesi, M Mazzotta, E Krasniqi, L Pizzuti, D Marinelli, E Capomolla, ... International journal of molecular sciences 21 (10), 3528, 2020 | 72 | 2020 |
| Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study G Bon, L Pizzuti, V Laquintana, R Loria, M Porru, C Marchiò, E Krasniqi, ... Journal of Experimental & Clinical Cancer Research 39, 1-14, 2020 | 54 | 2020 |
| KEAP1 and TP53 frame genomic, evolutionary, and immunologic subtypes of lung adenocarcinoma with different sensitivity to immunotherapy S Scalera, M Mazzotta, G Corleone, F Sperati, I Terrenato, E Krasniqi, ... Journal of Thoracic Oncology 16 (12), 2065-2077, 2021 | 43 | 2021 |
| Prognostic relevance of neutrophil to lymphocyte ratio (NLR) in luminal breast cancer: a retrospective analysis in the neoadjuvant setting A Grassadonia, V Graziano, L Iezzi, P Vici, M Barba, L Pizzuti, G Cicero, ... Cells 10 (7), 1685, 2021 | 33 | 2021 |
| Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review … D Marinelli, FT Gallina, S Pannunzio, MA Di Civita, A Torchia, R Giusti, ... Critical Reviews in Oncology/Hematology 192, 104190, 2023 | 30 | 2023 |
| Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence E Krasniqi, L Pizzuti, G Barchiesi, D Sergi, S Carpano, C Botti, R Kayal, ... Journal of cellular physiology 235 (11), 7900-7910, 2020 | 30 | 2020 |
| Circulating HPV DNA in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives E Krasniqi, M Barba, A Venuti, L Pizzuti, F Cappuzzo, L Landi, S Carpano, ... Journal of Clinical Medicine 10 (7), 1525, 2021 | 29 | 2021 |
| Nodal upstaging evaluation after robotic-assisted lobectomy for early-stage non-small cell lung cancer compared to video-assisted thoracic surgery and thoracotomy: a … FT Gallina, E Melis, D Forcella, E Mercadante, D Marinelli, S Ceddia, ... Frontiers in Surgery 8, 666158, 2021 | 27 | 2021 |
| TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients R Dinami, M Porru, CA Amoreo, I Sperduti, M Mottolese, S Buglioni, ... Journal of Experimental & Clinical Cancer Research 39, 1-13, 2020 | 24 | 2020 |
| Intraoperative graft verification in coronary surgery G Di Giammarco, D Marinelli, M Foschi, M Di Mauro Journal of Cardiovascular Medicine 18 (5), 295-304, 2017 | 23 | 2017 |
| Non-small-cell lung cancer: how to manage ALK-, ROS1-and NTRK-rearranged disease D Marinelli, M Siringo, G Metro, B Ricciuti, AJ Gelibter Drugs in Context 11, 2022 | 16 | 2022 |
| Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: Current evidence and literature-based meta-analysis of randomized trials D Marinelli, M Mazzotta, L Pizzuti, E Krasniqi, T Gamucci, C Natoli, ... Cancers 12 (9), 2497, 2020 | 16 | 2020 |
| MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study E Krasniqi, A Sacconi, D Marinelli, L Pizzuti, M Mazzotta, D Sergi, ... Biomarker research 9 (1), 57, 2021 | 14 | 2021 |
| Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes M Mazzotta, M Filetti, M Occhipinti, D Marinelli, S Scalera, I Terrenato, ... Journal for Immunotherapy of Cancer 8 (2), e000946, 2020 | 14 | 2020 |
| The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial L Pizzuti, M Barba, M Mazzotta, E Krasniqi, M Maugeri-Saccà, T Gamucci, ... Scientific Reports 11 (1), 13770, 2021 | 13 | 2021 |
| Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: The DE-REAL study A Botticelli, R Caputo, S Scagnoli, S Pisegna, M De Laurentiis, ... The Oncologist 29 (4), 303-310, 2024 | 12 | 2024 |
| Palliative-and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives D Marinelli, R Giusti, M Mazzotta, M Filetti, E Krasniqi, L Pizzuti, L Landi, ... Critical reviews in oncology/hematology 157, 103176, 2021 | 12 | 2021 |
| CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach. R Giusti, M Mazzotta, M Filetti, D Marinelli, A Di Napoli, S Scarpino, ... Journal of Clinical Oncology 37 (15_suppl), e20628-e20628, 2019 | 12 | 2019 |
| Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis BA Maiorano, M Di Maio, L Cerbone, E Maiello, G Procopio, G Roviello, ... JAMA network open 7 (3), e241215-e241215, 2024 | 9 | 2024 |